AlzChem Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
AlzChem Group heeft een totaal eigen vermogen van €182.6M en een totale schuld van €53.6M, wat de schuld-eigenvermogensverhouding op 29.3% brengt. De totale activa en totale passiva bedragen respectievelijk €463.4M en €280.9M. De EBIT AlzChem Group is €66.8M waardoor de rentedekking 26.4 is. Het heeft contanten en kortetermijnbeleggingen van €46.1M.
Belangrijke informatie
29.3%
Verhouding schuld/eigen vermogen
€53.55m
Schuld
| Rente dekkingsratio | 26.4x |
| Contant | €46.07m |
| Aandelen | €182.55m |
| Totaal verplichtingen | €280.87m |
| Totaal activa | €463.43m |
Recente financiële gezondheidsupdates
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07
Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11Recent updates
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( €255.9M ) ACT } overtreffen de korte termijn passiva ( €109.9M ).
Langlopende schulden: De kortetermijnactiva ACT ( €255.9M ) overtreffen de langetermijnschulden ( €170.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 4.1% ) ACT wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van ACT is de afgelopen 5 jaar gedaald van 150.7% naar 29.3%.
Schuldendekking: De schuld van ACT wordt goed gedekt door de operationele kasstroom ( 180.5% ).
Rentedekking: De rentebetalingen op de schuld van ACT worden goed gedekt door EBIT ( 26.4 x dekking).